10x Genomics (TXG) Revenue (2018 - 2026)

10x Genomics' Revenue history runs 9 years deep, the most recent figure standing at $150.8 million for Q1 2026.

• In Q1 2026, Revenue fell 2.61% year-over-year to $150.8 million; the TTM figure through Mar 2026 stood at $638.8 million (up 2.26% YoY), while the FY2025 annual figure was $642.8 million, up 5.25% from the prior year.
• Revenue came in at $150.8 million for Q1 2026 at 10x Genomics, down from $166.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $184.0 million in Q4 2023 to a low of $114.5 million in Q1 2022.
• A 5-year average of $149.4 million and a median of $151.7 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue gained 28.1% in 2023 and slipped 10.3% in 2024, its largest moves.
• 10x Genomics' Revenue stood at $156.2 million in 2022, then gained by 17.76% to $184.0 million in 2023, then retreated by 10.3% to $165.0 million in 2024, then rose by 0.61% to $166.0 million in 2025, then fell by 9.15% to $150.8 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $150.8 million, $166.0 million, and $149.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison